We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
2.80 | 8.24% | 36.80 | 36.60 | 37.30 | 37.30 | 35.00 | 35.00 | 753,383 | 16:35:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -18.81 | 109.76M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/3/2023 12:07 | LBO has no life, no work to do, and no one to talk to. All very sad... | joestalin | |
19/3/2023 11:50 | Joe unlike the people you publicly said were ‘clueless oafs’! Presumably they sleep very well! LOL JoeStalin - 02 Dec 2018 - 12:13:30 - 4655 of 17404 If there was a competition for bumbling clueless oaf of the year then Barder and Theresa May will be battling for first place. | lbo | |
19/3/2023 11:35 | LiarBO, 'Above all, don't lie to yourself. The man who lies to himself and listens to his own lie comes to a point that he cannot distinguish the truth within him, or around him, and so loses all respect for himself and for others.' Dostoevsky | petroc | |
19/3/2023 11:24 | He never sleeps. | joestalin | |
19/3/2023 10:08 | Here we go !!!! (From the web) What’s so special about this gel? Published in February 2018, a clinical trial showed fantastic results for Eroxon with the key factor being how fast it worked: Within 5 minutes of applying the gel it was successful in 44% of men and within 10 minutes this success rate was 70%. If you compare this to the current erectile dysfunction tablets that are the gold standard in treatment, they range from 15 minutes to over an hour to have their effect (depending on the brand and other factors such as stomach contents). Viagra, or it’s generic version Sildenafil, are the most commonly used treatments and should be taken around one hour before intercourse. | mikethebike4 | |
18/3/2023 19:17 | The problem Petroc the proven multi-iD ramper has is he can never substantiate any of his false and misleading claims with any non deficient evidence. But it can be substantiated that he himself has proven the results from the deficient FM57 which was not even designed to study the placebo gel and are a ‘false positive’ ‘post hoc finding’ It was him who provided the evidence from the HCP UK website which he is now desperately trying to bury and deflect from! ‘Eroxon was the placebo used in FM57’ So now thanks to Petroc public complaints can now be made about Med3000/Eroxon to the ASA. Its all thanks to Petroc that yet more evidence of how one misleading claim can lead to multi-ID rampers making many more false and misleading claims. All based on a flawed assumption from a false positive post hoc analysis of a study set up to study something completely different. And the application of the same subject principles of the ASA ruling on another similar drug free Class 2b medical device gel to Med3000/Eroxon. Can now mean the ASA can also find similarly that the supposedly surprising results of FM57 are actually just a ˜post hoc finding’ and ˜false positive’ Med3000 was just the placebo in the FM57 study Therefore Futura had initially believed Med3000 had no therapeutic effect. The FM57 study did not set out to measure the efficacy of Med3000. The ASA will therefore consider that its reported effectiveness by Futura was a â€ËÅ The CAP Code required that objective claims, including medical claims for a CE-marked medical device, be backed by evidence a certified Class IIb medical device. We understood that the device certification was granted by a body within the European Member States that had been designated to carry out conformity assessments under the Medical Device Directive had been used as the placebo treatment in that study, and therefore the researcher had initially believed it had no therapeutic effect. The trial did not set out to measure the efficacy its reported effectiveness by the advertiser was a post-hoc finding due to the risk of that being a false positive finding | lbo |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions